Board Change • May 20
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 3 experienced directors. 8 highly experienced directors. 3 independent directors (7 non-independent directors). Independent Director Beatrice Saunier was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Annonce • May 07
Cegedim SA, Annual General Meeting, Jun 12, 2026 Cegedim SA, Annual General Meeting, Jun 12, 2026. Location: 114 rue d aguesseau, boulogne billancourt France Board Change • Dec 30
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 4 experienced directors. 7 highly experienced directors. 3 independent directors (7 non-independent directors). Independent Director Beatrice Saunier was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Annonce • May 10
Cegedim SA, Annual General Meeting, Jun 13, 2025 Cegedim SA, Annual General Meeting, Jun 13, 2025. Location: 114 rue d aguesseau, boulogne billancourt France Annonce • Apr 25
Cegedim SA Provides Group Earnings Guidance for the Full Year of 2025 Cegedim SA provided group earnings guidance for the full year of 2025. Based on the currently available information, the group expects 2025 like-for-like revenue growth at constant scope and exchange rates to be in the range of 2% to 4% relative to 2024. Recurring operating income should continue to improve, following a similar trajectory as in 2024. These targets are not forecasts and may need to be revised if there is a significant worsening of geopolitical, macroeconomic, or currency risks. Reported Earnings • Sep 29
First half 2024 earnings released: EPS: €0.046 (vs €0.64 loss in 1H 2023) First half 2024 results: EPS: €0.046 (up from €0.64 loss in 1H 2023). Revenue: €319.0m (up 6.0% from 1H 2023). Net income: €630.0k (up €9.42m from 1H 2023). Profit margin: 0.2% (up from net loss in 1H 2023). Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 55 percentage points per year, which is a significant difference in performance. Annonce • Sep 27
Cegedim SA Provides Earnings Guidance for the Full Year 2024 Cegedim SA provided earnings guidance for the full year 2024. Based on the currently available information, the Group expects 2024 like-for-like revenue growth to be in the range of 5%-8% relative to 2023. Recurring operating income should continue to improve, following a similar trajectory as in 2023. Recurring operating income is expected to grow, notably the initial returns on investments made in Cegedim Santé and refocusing international activities. These targets may need to be revised in the event of unexpected developments (pandemic, etc.) and/or a significant worsening of geopolitical and macroeconomic risks. The Group reiterates that it has no activities or exposed assets in Russia or Ukraine. Reported Earnings • Mar 29
Third quarter 2023 earnings released: EPS: €0.051 (vs €0.68 in 3Q 2022) Third quarter 2023 results: EPS: €0.051 (down from €0.68 in 3Q 2022). Revenue: €157.5m (up 9.5% from 3Q 2022). Net income: €693.0k (down 93% from 3Q 2022). Profit margin: 0.4% (down from 6.4% in 3Q 2022). Revenue is forecast to grow 5.8% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has fallen by 19% per year whereas the company’s share price has fallen by 20% per year. Valuation Update With 7 Day Price Move • Mar 27
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to €13.60, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 16x in the Healthcare Services industry in Europe. Total loss to shareholders of 42% over the past three years. Reported Earnings • Nov 24
First half 2023 earnings released: €0.64 loss per share (vs €0.36 loss in 1H 2022) First half 2023 results: €0.64 loss per share (further deteriorated from €0.36 loss in 1H 2022). Revenue: €301.0m (up 13% from 1H 2022). Net loss: €8.79m (loss widened 80% from 1H 2022). Revenue is forecast to grow 6.8% p.a. on average during the next 3 years, compared to a 8.6% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Annonce • Oct 28
Cegedim Provides Revenue Guidance for the Full Year 2023 Cegedim provides revenue guidance for the full year 2023. Based on nine-month 2023 revenues up 11.9% like for like, and despite the public health, economic, geopolitical, and monetary uncertainty facing the world, the Group is confident it can grow full-year revenues by 11% to 12% and improve its recurring operating income. Reported Earnings • Sep 22
First half 2023 earnings released: €0.64 loss per share (vs €0.36 loss in 1H 2022) First half 2023 results: €0.64 loss per share (further deteriorated from €0.36 loss in 1H 2022). Revenue: €301.0m (up 13% from 1H 2022). Net loss: €8.79m (loss widened 80% from 1H 2022). Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 7.6% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Annonce • Jul 29
Cegedim SA Provides Revenue Guidance for the Full Year 2023 Cegedim SA provided revenue guidance for the full year 2023. For the year, the company expects Based on H1 2023 revenues up 12.1% like for like, and despite the public health, economic, geopolitical, and monetary uncertainty facing the world, the Group is confident it can grow full-year revenues by at least 10% like for like(1) and improve its recurring operating income. Valuation Update With 7 Day Price Move • Mar 30
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to €19.32, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 24x in the Healthcare Services industry in Europe. Total loss to shareholders of 14% over the past three years. Reported Earnings • Mar 25
Full year 2022 earnings released: EPS: €1.00 (vs €1.90 in FY 2021) Full year 2022 results: EPS: €1.00 (down from €1.90 in FY 2021). Revenue: €555.2m (up 5.8% from FY 2021). Net income: €13.6m (down 48% from FY 2021). Profit margin: 2.5% (down from 5.0% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 8.5% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Annonce • Jan 28
Cegedim SA Provides Group Revenue Guidance for the Year 2023 Cegedim SA provided group revenue guidance for the year 2023. For the year, the Group expects 2023 revenue growth in the range of 6% to 9% compared to 2022. Board Change • Nov 16
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 5 experienced directors. 5 highly experienced directors. 3 independent directors (7 non-independent directors). Independent Director Beatrice Saunier was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Annonce • Nov 08
Cegedim SA to Report Fiscal Year 2022 Results on Mar 23, 2023 Cegedim SA announced that they will report fiscal year 2022 results After-Market on Mar 23, 2023 Valuation Update With 7 Day Price Move • Sep 27
Investor sentiment deteriorated over the past week After last week's 27% share price decline to €13.86, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 32x in the Healthcare Services industry in Europe. Total loss to shareholders of 45% over the past three years. Annonce • Sep 22
Cegedim Provides Revenue Guidance for 2022 Cegedim still expects like-for-like revenue growth of c.5% in 2022. Reported Earnings • Sep 21
First half 2022 earnings released: €0.40 loss per share (vs €0.47 profit in 1H 2021) First half 2022 results: €0.40 loss per share (down from €0.47 profit in 1H 2021). Revenue: €267.6m (up 6.5% from 1H 2021). Net loss: €4.90m (down 176% from profit in 1H 2021). Revenue is forecast to grow 4.3% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 71% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Annonce • Jun 23
Cegedim SA (ENXTPA:CGM) acquired Merito, SAS. Cegedim SA (ENXTPA:CGM) acquired Merito, SAS on June 22, 2022.
Cegedim SA (ENXTPA:CGM) completed the acquisition of Merito, SAS on June 22, 2022. Upcoming Dividend • Jun 22
Upcoming dividend of €0.50 per share Eligible shareholders must have bought the stock before 29 June 2022. Payment date: 01 July 2022. Trailing yield: 2.1%. Lower than top quartile of German dividend payers (4.4%). Higher than average of industry peers (1.4%). Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 7 non-independent directors. Independent Director Beatrice Saunier was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Mar 03
Investor sentiment improved over the past week After last week's 32% share price gain to €26.55, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 29x in the Healthcare Services industry in Europe. Total returns to shareholders of 8.8% over the past three years. Annonce • Mar 03
Cegedim, Malakoff Humanis, Groupe VYV, PRO BTP in Talks for Acquisition of Equity Stake in Cegedim Santé Cegedim SA (ENXTPA:CGM) and Malakoff-Médéric SARL (Malakoff Humanis), UMG Groupe VYV, and PRO BTP are in talks regarding the acquisition of an equity stake in Cegedim Santé, the Group subsidiary specialized in digital solutions for healthcare professionals and patients. As part of the deal, Cegedim Santé will simultaneously acquire SAS TBNO Invest (MesDocteurs), Groupe VYV’s subsidiary specializing in telehealth. Once negotiations are complete, the deal will be sealed by the signature of an investment agreement and a strategic and industrial partnership between Cegedim, Malakoff Humanis, Groupe VYV, and PRO BTP. The transaction will be complete once employee representatives issue an opinion. “We are delighted to see the interest expressed by such high-caliber healthcare sector players as Malakoff Humanis, Groupe VYV, and PRO BTP. By joining us, these groups—which represent 25 million beneficiaries in France—will strengthen Cegedim Santé’s position as the recognized French leader in IT for doctors in private practice, with 100,000 healthcare professional users. This deal signals Cegedim Santé’s determination to innovate and develop solutions for healthcare professionals and patients in France,” stated Jean-Claude Labrune, Cegedim Chairman & CEO. Advising Cegedim Group in the talks are investment bank Ohana & Co. and the law firm Goodwin. Malakoff Humanis, Groupe VYV, and PRO BTP are advised by Rothschild & Co, PwC Corporate Finance, PwC Transactions Services, and the law firm Darrois Villey Maillot Brochier. Annonce • Jan 30
Cegedim SA Provides Revenue Guidance for the Year 2022 Cegedim SA provided revenue guidance for the year 2022. For the year, the company expects revenue will probably have roughly the same increase than in 2021. Annonce • Jan 28
Cegedim SA to Report First Half, 2022 Results on Sep 20, 2022 Cegedim SA announced that they will report first half, 2022 results on Sep 20, 2022 Annonce • Sep 19
Cegedim Provides Revenue Guidance for the Year 2021 Cegedim provided revenue guidance for the year 2021. For the year, the Group expects like-for-like revenue growth of 3% to 5%. The Group reiterates its target for recurring operating income(1) of around 4%. Reported Earnings • Sep 18
First half 2021 earnings released: EPS €0.47 (vs €0.34 loss in 1H 2020) The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: €251.2m (up 6.4% from 1H 2020). Net income: €6.50m (up €11.2m from 1H 2020). Profit margin: 2.6% (up from net loss in 1H 2020). Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Annonce • Apr 29
Cegedim Provides Revenue Guidance for the Year 2021 Cegedim provided revenue guidance for the year 2021. With first quarter 2021 like-for-like revenues up 1.0%, the Group maintains its 2021 growth forecasts of about 2% in like-for-like revenue and about 4% in recurring operating income. Reported Earnings • Mar 20
Full year 2020 earnings released: EPS €0.78 (vs €0.20 in FY 2019) The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2020 results: Revenue: €496.9m (down 1.4% from FY 2019). Net income: €10.8m (up 302% from FY 2019). Profit margin: 2.2% (up from 0.5% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 11% per year, which means it is performing significantly worse than earnings. Annonce • Mar 19
Cegedim SA Provides Earnings Guidance for the Year 2021 Cegedim SA provided earnings guidance for the year 2021. For the year, the company's outlook for 2021 is to see revenue up by around 2% and recurring operating income increased by around 4%. Is New 90 Day High Low • Feb 24
New 90-day low: €23.10 The company is down 4.0% from its price of €24.00 on 26 November 2020. The German market is up 7.0% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Healthcare Services industry, which is also down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €41.23 per share. Valuation Update With 7 Day Price Move • Dec 03
Market bids up stock over the past week After last week's 15% share price gain to €27.70, the stock is trading at a trailing P/E ratio of 47.2x, up from the previous P/E ratio of 40.9x. This compares to an average P/E of 46x in the Healthcare Services industry in Europe. Total return to shareholders over the past three years is a loss of 14%. Is New 90 Day High Low • Dec 02
New 90-day high: €27.50 The company is up 5.0% from its price of €26.30 on 03 September 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. However, its price trend is similar to the Healthcare Services industry, which is also up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €38.37 per share. Is New 90 Day High Low • Oct 31
New 90-day low: €22.50 The company is down 17% from its price of €27.20 on 31 July 2020. The German market is down 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare Services industry, which is up 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €43.13 per share. Is New 90 Day High Low • Sep 19
New 90-day low: €23.50 The company is down 16% from its price of €28.00 on 19 June 2020. The German market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare Services industry, which is up 15% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €54.28 per share. 
